Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

August 28, 2023

Study Completion Date

August 28, 2023

Conditions

Advanced Malignancies

Interventions

BIOLOGICAL

IBI322

Recombinant anti-human CD47/PD-L1 bispecific antibody injection

Trial Locations (1)

Cancer hospital Chinese academy of Medical sciences, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04328831 - Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter